ADVL 1515: A Phase 1 Study of LY2606368, A CHK 1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors

Grant

Date/time Interval

  • June 28, 2017 - June 27, 2020

    • Awarded By

    Total Award Amount

  • 6500.00

    • Direct Costs

  • 5000.00

    • Sponsor Award Id

    • Contributor

  • Alva, Elizabeth   Investigator  
  • Aye, Jamie   Investigator  
  • Friedman M.D., Gregory   Principal Investigator  
  • Galtarossa Xavier, Ana   Investigator  
  • Johnston, Emily   Investigator  
  • Kutny M.D., Matthew   Investigator  
  • Liang, Wayne   Investigator  
  • Metrock, Laura   Investigator  
  • Whelan M.D., Kimberly   Investigator